{
    "ticker": "LYEL",
    "name": "Lyell Immunopharma, Inc.",
    "description": "Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing advanced cell therapies for cancer treatment. Founded in 2018 and headquartered in South San Francisco, California, Lyell is dedicated to engineering T cells to enhance their ability to recognize and destroy cancer cells. The company's innovative approach combines cutting-edge genetic engineering techniques with a commitment to harnessing the body's immune system to fight cancer. Lyell's proprietary platforms, including its Lyell T-cell platform, are designed to create durable and effective T-cell therapies that can overcome the challenges of tumor microenvironments. With a robust pipeline of product candidates, Lyell aims to bring transformative therapies to patients suffering from various forms of cancer, including solid tumors. The company's mission is to improve the lives of patients with cancer by enabling their immune systems to effectively target and eliminate malignant cells, thereby enhancing long-term outcomes and quality of life. As Lyell progresses through clinical trials, it continues to work towards partnerships and collaborations that will accelerate the development of its promising therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2018",
    "website": "https://www.lyell.com",
    "ceo": "Katherine (Katie) K. A. McCarthy",
    "social_media": {
        "twitter": "https://twitter.com/LyellImmuno",
        "linkedin": "https://www.linkedin.com/company/lyell-immunopharma/"
    },
    "investor_relations": "https://investors.lyell.com",
    "key_executives": [
        {
            "name": "Katherine McCarthy",
            "position": "CEO"
        },
        {
            "name": "Diana B. D. H. N. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy",
            "products": [
                "LYL132",
                "LYL331"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lyell Immunopharma, Inc. | Advanced Cell Therapies for Cancer",
        "meta_description": "Lyell Immunopharma, Inc. is focused on developing innovative T cell therapies for cancer treatment. Discover our mission, products, and clinical pipeline.",
        "keywords": [
            "Lyell Immunopharma",
            "Cell Therapy",
            "Cancer Treatment",
            "T Cells",
            "Biotechnology",
            "Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What is Lyell Immunopharma known for?",
            "answer": "Lyell Immunopharma is known for developing advanced cell therapies targeting cancer."
        },
        {
            "question": "Who is the CEO of Lyell Immunopharma?",
            "answer": "Katherine McCarthy is the CEO of Lyell Immunopharma, Inc."
        },
        {
            "question": "Where is Lyell Immunopharma headquartered?",
            "answer": "Lyell Immunopharma is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Lyell Immunopharma's main products?",
            "answer": "Lyell Immunopharma's main products include LYL132 and LYL331, both of which are under development for cancer treatment."
        },
        {
            "question": "When was Lyell Immunopharma founded?",
            "answer": "Lyell Immunopharma was founded in 2018."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "ZTS"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "REGN"
    ]
}